2015 ISAKOS Biennial Congress ePoster #1432
Financial Benefits of Intra-Articular Tranexamic Acid in Total Knee Arthroplasty
Navendu Goyal, MBBS ,MS(Ortho) , DNB (Ortho), Panchkula, Haryana INDIA
Samuel John Macdessi, MBBS, FRACS, Sydney, NSW AUSTRALIA
Darren Chen, FRACS, Kogarah, NSW AUSTRALIA
Ian A. Harris, MB, BS, Sydney, NSW AUSTRALIA
George Kirsh, FRACS, Sydney AUSTRALIA
Neville Rowden, FRACS, Sydney AUSTRALIA
St George Private Hospital, Sydney, NSW, AUSTRALIA
FDA Status Cleared
Summary: Use of intra-articular TXA significantly decreased the number of patients who were transfused, number of blood transfusions and length of stay which brought about an overall decrease in health care costs.
The aim of this study was to evaluate financial benefits of intra-articular tranexamic acid [TXA] in total knee arthroplasty [TKA].
We analyzed retrospective data for 1981 patients who underwent primary TKA with intra-articular injection of TXA in to the knee joint following wound closure.
The number of patients receiving transfusion decreased from 14.7% to 4.5% with TXA use (p-value <0.0001). The number of units transfused per 100 patients decreased from 32.1 units to 8.5 units with TXA use [p-value <0.0001]. Mean length of stay decreased by 0.6 days, from 5.3 (SD 2.7) days to 4.7 [SD 2.3] days (p < 0.0001]). Overall, there was total health care cost saving of $631.35 per patient.
Use of intra-articular TXA significantly decreased the number of patients who were transfused, number of blood transfusions and length of stay which brought about an overall decrease in health care costs.